Intellia Therapeutics (NASDAQ:NTLA) Earns “Neutral” Rating from William Blair

William Blair restated their neutral rating on shares of Intellia Therapeutics (NASDAQ:NTLA) in a research report released on Monday morning,RTT News reports. William Blair currently has a $14.00 price objective on the stock.

Other analysts also recently issued reports about the company. JPMorgan Chase & Co. dropped their price objective on Intellia Therapeutics from $61.00 to $55.00 and set an “overweight” rating for the company in a report on Monday, August 12th. Oppenheimer lowered their price target on Intellia Therapeutics from $70.00 to $60.00 and set an “outperform” rating for the company in a research report on Monday, November 11th. The Goldman Sachs Group cut their price objective on Intellia Therapeutics from $31.00 to $20.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. StockNews.com upgraded Intellia Therapeutics to a “sell” rating in a report on Friday, November 8th. Finally, Robert W. Baird cut their price target on shares of Intellia Therapeutics from $24.00 to $18.00 and set a “neutral” rating on the stock in a report on Friday, October 25th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, eleven have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat, Intellia Therapeutics presently has a consensus rating of “Moderate Buy” and an average target price of $54.94.

Intellia Therapeutics Price Performance

NTLA opened at $13.12 on Monday. The stock has a market capitalization of $1.34 billion, a price-to-earnings ratio of -2.41 and a beta of 1.81. Intellia Therapeutics has a 12 month low of $12.82 and a 12 month high of $34.87. The business has a 50-day moving average of $18.40 and a two-hundred day moving average of $21.91.

Intellia Therapeutics (NASDAQ:NTLA) last released its earnings results on Thursday, November 7th. The company reported ($1.34) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($1.37) by $0.03. The company had revenue of $9.10 million during the quarter, compared to analysts’ expectations of $8.28 million. Intellia Therapeutics’s revenue for the quarter was down 24.1% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($1.38) earnings per share. Equities research analysts anticipate that Intellia Therapeutics will post -5.13 earnings per share for the current year.

Insider Transactions at Intellia Therapeutics

In other news, CAO Michael P. Dube sold 2,012 shares of the firm’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $19.01, for a total transaction of $38,248.12. Following the completion of the sale, the chief accounting officer now owns 47,012 shares of the company’s stock, valued at approximately $893,698.12. This trade represents a 4.10 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Corporate insiders own 3.20% of the company’s stock.

Institutional Inflows and Outflows

Hedge funds have recently added to or reduced their stakes in the stock. Blue Trust Inc. lifted its position in shares of Intellia Therapeutics by 1,664.3% during the second quarter. Blue Trust Inc. now owns 1,482 shares of the company’s stock worth $33,000 after purchasing an additional 1,398 shares during the last quarter. EverSource Wealth Advisors LLC lifted its holdings in Intellia Therapeutics by 763.5% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 1,753 shares of the company’s stock worth $39,000 after buying an additional 1,550 shares during the last quarter. Eastern Bank acquired a new position in shares of Intellia Therapeutics in the 3rd quarter worth approximately $41,000. Values First Advisors Inc. bought a new stake in shares of Intellia Therapeutics in the 3rd quarter valued at approximately $54,000. Finally, First Horizon Advisors Inc. raised its position in shares of Intellia Therapeutics by 22.1% during the 2nd quarter. First Horizon Advisors Inc. now owns 2,604 shares of the company’s stock valued at $58,000 after acquiring an additional 472 shares in the last quarter. 88.77% of the stock is owned by institutional investors and hedge funds.

Intellia Therapeutics Company Profile

Intellia Therapeutics, Inc, a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease.